PhRMA Launches Advertising and Public Affairs Initiative

Article

The organization launched its GOBOLDLY campaign to highlight the work of US biopharmaceutical companies.

On Jan. 23, 2017 the Pharmaceutical Research and Manufacturers of America (PhRMA) announced the launch of a multi-year advertising and public affairs initiative on behalf of US biopharmaceutical companies. The campaign is titled GOBOLDLY and will include national television, print, digital, radio and out-of-home advertising focused on highlighting the work of biopharmaceutical companies.

According to PhRMA, the ad campaign highlights revolutionary biopharmaceutical science. The first television advertisement in the campaign features the Dylan Thomas poem Do Not Go Gentle. In addition to paid advertising, the campaign will include public affairs activities to foster a national dialogue with researchers, caregivers, patients, and policymakers in forums around the country. These discussions will focus on what the new era in medicine means for patients and the health care system and the types of public policy solutions that are needed to sustain progress.

“Through partnerships and collaborations with other health care leaders, we will work to advance commonsense solutions that foster the continued development of new medicines, enhance the private marketplace and provide patients with access to the newest and most innovative treatments,” said Stephen J. Ubl, president and CEO of PhRMA, in a statement.

The campaign will include three distinct public affairs initiatives around the following core areas: bold advancements in science, value-driven health care, and public health. These efforts will officially kick off in February and March 2017.

Source: PhRMA

 

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.